Form 4: Halozyme Therapeutics Director Krishnan Mahesh Reports Stock and Option Grants

Director Krishnan Mahesh reports acquisition of restricted stock units and stock options in Halozyme Therapeutics.

Summary

• On May 1, 2025, Director Krishnan Mahesh acquired 4,165 shares of common stock through a restricted stock unit (RSU) grant and disposed of 0 shares.
• Following the transaction, Mahesh directly owns 10,666 shares of common stock.
• Mahesh also acquired an option to purchase 5,750 shares of common stock at an exercise price of $60.03, expiring on May 1, 2035.
• The RSU and stock option grants vest fully on the earlier of May 1, 2026, or the date of the Issuer's next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices, indicating stability and alignment of interests. It's a neutral but positive signal.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the grants.

Industry Context

This filing is a routine disclosure of insider transactions, common in the pharmaceutical and biotechnology industries to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices for directors in publicly traded biotechnology companies like Halozyme.
• Companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their board members.
• The vesting schedules, typically one year, are also in line with industry norms to ensure continued alignment with shareholder value.

Stakeholder Impact

• Shareholders: The grants align director interests with shareholder value.
• Employees: The grants are part of the overall compensation structure.

Key Dates

Keywords

Form 4, Halozyme Therapeutics, Director Compensation, Stock Options, Restricted Stock Units, Insider Trading, Beneficial Ownership, Krishnan Mahesh